Clinical and Translational Medicine is an open access journal accelerating the translation of preclinical research to a clinical application and the communication between basic and clinical scientists. We're proudly open access with a global audience of clinicians, researchers, and policy makers.

Why publish in Clinical and Translational Medicine?

  • Enjoy a rapid turnaround time for submissions, with a first decision granted within an average of 8 days.
  • Highly ranked in the fields of Research & Experimental Medicine and Oncology (SCI Index).
  • Your work will be discoverable and widely distributed with indexing by MEDLINE, PubMed Central, SCIE, Web of Science and Directory of Open Access Journals.
  • Your research will be open access, making it freely available to read, download and share with ease.
  • Publish alongside quality and impactful research governed by a distinguished Editor-in-Chief and prestigious, international Editorial Board.

Clinical and Translational Medicine focuses on the bench to bedside approach, favoring studies and clinical observations which generate hypotheses and questions relevant to the patient and disease, and guide the investigations of cellular and molecular medicine.

Submissions from clinicians, researchers, policy makers, and industry are welcome.

Submit your paper here.

Skip slideshow

Articles

RESEARCH ARTICLE
Open access

Elucidating epigenetic landscape of gastric premalignant lesions through genome‐wide mapping of 5‐hydroxymethylcytosines: A 12‐year median follow‐up study

  •  3 December 2024

Graphical Abstract

Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-year median follow-up study Issue 12, 2024

  • A largest longitudinal follow-up study of gastric precursor lesions in Chinese patients.
  • Revealing novel 5hmC molecular landscape linked to gastric premalignant lesions.
  • The feasibility of an innovative 5hmC-based predictive model for assessing gastric cancer progression risk.

RESEARCH ARTICLE
Open access

Glucose‐induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma

  •  3 December 2024

Graphical Abstract

Glucose-induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma Issue 12, 2024

  • This study highlights the considerable regulatory role of LINC01419 in the metabolism of HCC.
  • The newly identified LINC01419/YBX1-PDK1 axis constitutes a valuable target.
  • Hepatic-specific delivery of GalNAc-siLINC01419 presents a promising therapeutic strategy for HCC.
.

RESEARCH ARTICLE
Open access

Extracellular vesicles derived from creeping fat stem cells promote lymphatic function and restrain inflammation of Crohn's disease

  •  2 December 2024

Graphical Abstract

Extracellular vesicles derived from creeping fat stem cells promote lymphatic function and restrain inflammation of Crohn's disease Issue 12, 2024

1. Extracellular vesicles (EVs) derived from adipose tissue-derived stem cells in creeping fat (CrF) improve lymphatic functions and increase mesenteric lymphatic vessel density of Il-10-/– mice, leading to decreased colitis and mesenteritis through the miR-132-3p/RASA1 /ERK1/2 axis.

2. Co-culturing human lymphatic endothelial cells with CrF-EVs promotes proliferation, migration and tube function in vitro.

3. Upregulated miR-132-3p in CrF was negatively correlated with proinflammatory cytokines. Moreover, serum miR-132-3p was positively correlated with disease activity.

REVIEW
Open access

The role of the interplay between macrophage glycolytic reprogramming and NLRP3 inflammasome activation in acute lung injury/acute respiratory distress syndrome

  •  2 December 2024

Graphical Abstract

The role of the interplay between macrophage glycolytic reprogramming and NLRP3 inflammasome activation in acute lung injury/acute respiratory distress syndrome Issue 12, 2024

  • NLRP3 inflammasome activation is pivotal in mediating the excessive inflammatory response in ALI/ARDS.
  • Glycolytic reprogramming regulates NLRP3 inflammasome activation.
  • Therapeutic potential of targeting glycolytic reprogramming to inhibit NLRP3 inflammasome activation in ALI/ARDS.

RESEARCH ARTICLE
Open access

The gut microbiota‐derived metabolite indole‐3‐propionic acid enhances leptin sensitivity by targeting STAT3 against diet‐induced obesity

  •  28 November 2024

Graphical Abstract

The gut microbiota-derived metabolite indole-3-propionic acid enhances leptin sensitivity by targeting STAT3 against diet-induced obesity Issue 12, 2024

  • IPA-based gut-brain axis regulates host metabolism.

  • IPA is a leptin sensitiser.

  • STAT3 protein is the target of IPA.

  • The circulating levels of IPA are affected by a high-fat diet.

More articles
More articles
More articles

Recent issues

Latest news